The rsk1 gene encodes the 90 kDa ribosomal S6 kinase 1 (RSK1) protein, which contains two kinase domains. RSK1, which is involved in regulating cell survival and proliferation, lies at the end of the signaling cascade mediated by the extracellular signal-regulated kinase (ERK) subfamily of mitogen-activated protein (MAP) kinases. ERK activation and subsequent phosphorylation of the RSK1 carboxy-terminal catalytic loop stimulates phosphotransferase activity in the RSK1 amino-terminal kinase domain. When activated, RSK1 phosphorylates both nuclear and cytoplasmic substrates through this amino-terminal catalytic domain. It is thought that stimulation of the ERK/MAP kinase pathway is sufficient for RSK1 activation, but how ERK phosphorylation activates the RSK1 amino-terminal kinase domain is not known.
Background
Mitogenic stimuli activate the ribosomal S6 kinase 1 (RSK1) through the pathway involving the extracellular signal-regulated kinase (ERK) subfamily of mitogen-activated protein (MAP) kinases. Generation of the GTPbound form of Ras initiates a kinase cascade whereby Raf kinases activates MAP kinase kinase (MEK), which activates ERK1/ERK2, which in turn phosphorylates RSK1 (reviewed in [1] ). RSK1 is a serine/threonine kinase with two distinct kinase domains, both of which are catalytically functional [2] . The carboxy-terminal kinase domain is believed to be involved in autophosphorylation, a critical feature of RSK1 activation, whereas the amino-terminal kinase domain is responsible for the phosphorylation of all exogenous substrates tested.
RSK is cytoplasmic, but it can translocate to the nucleus upon mitogenic stimulation [3] . Activated RSK has both cytoplasmic and nuclear substrates. Phosphorylation of the apoptotic protein BAD by RSK can protect cells from BAD-mediated cell death (A.S., unpublished observations).
RSK also phosphorylates IκBα, the inhibitor of the transcription factor NF-κB, inducing degradation of IκBα and allowing NF-κB to translocate to the nucleus [4] . RSK plays an important role in nuclear signaling by phosphorylating various transcription factors, including the cyclic AMP (cAMP) response element binding protein (CREB) [5, 6] and c-Fos [7, 8] ; RSK therefore has a role in transcriptional regulation. RSK has also been implicated in cellcycle regulation. In Xenopus extracts RSK phosphorylates and downregulates Myt1, a p34 cdc2 inhibitory kinase [9] . Downregulation of Myt1 leads to activation of cyclin B-p34 cdc2 kinase and cell-cycle progression. Therefore, RSK has been implicated in a myriad of cellular processes, but its cellular role and substrate(s) remain unclear. The diversity of its substrates suggests that RSK may participate in cell proliferation and differentiation through multiple pathways.
Other than the requirements for ERK and autophosphorylation, relatively little is known about the mechanism of RSK regulation. The presence of two active kinase domains within the enzyme undoubtedly increases the complexity of studying this regulation. Six phosphorylation sites have been identified in RSK1, two of which are basally phosphorylated, and four of which are phosphorylated upon mitogen stimulation [10] . Among the mitogen-responsive sites are a putative ERK phosphorylation site in the RSK1 carboxyl terminus [11] and a putative RSK1 autophosphorylation site in the linker region between the two RSK1 kinase domains [12] . While sequence comparison suggests that the remaining sites may be ERK or RSK1 phosphorylation sites, it is possible that they are phosphorylated by other kinases. ERK alone is not capable of fully activating RSK1 in vitro [13] , suggesting that additional input(s) may be required for full RSK1 activation.
The RSK amino-terminal kinase domain has homology to other kinase domains, including those in cAMP-dependent protein kinase A (PKA) and p70 S6 kinase 1 (p70 S6K1 ) [14] . An important regulatory enzyme for PKA and p70 S6K1 is phosphoinositide-dependent kinase 1 (PDK1). PDK1 phosphorylates a site in the activation loops of protein kinase Bα (PKBα, also known as c-Akt) [15, 16] , various protein kinase Cs (PKCs) [17] [18] [19] , PKA [20] and p70 S6K1 [21, 22] . PDK1 is a protein of 556 amino acids that contains a kinase domain and a pleckstrin homology (PH) domain [15, 16] . The PH domain binds phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P 3 ) generated by phosphoinositide (PI) 3-kinases [23] . PDK1 is found in the cell cytosol and at the plasma membrane [23, 24] .
We are interested in the regulation of the individual RSK1 kinase domains. Here, we report that each isolated RSK1 kinase domain can be activated. Surprisingly, PDK1 could activate an isolated RSK1 amino-terminal kinase domain in vivo, but activation of the full-length protein required cooperation with the ERK/MAP-kinase pathway. We propose a model for RSK1 activation that incorporates regulatory inputs from the ERK/MAP-kinase pathway and additional phosphorylation events.
Results

Activation of isolated RSK1 kinase domains
Studies in vitro have indicated that both RSK1 kinase domains are active [2] . It has not, however, been determined whether or how each isolated kinase domain is activated in vivo. Because the regulation of each kinase domain could be different, knowing whether the two domains are independently activated would be useful in identifying the requirements for activation of full-length RSK1. Therefore, the RSK1 constructs D1, D1′ and D2 were generated (Figure 1 ). D1 and D1′ encode the aminoterminal kinase domain, with the only difference being an additional 56 amino acids in D1′. This additional sequence includes Ser398, which is analogous to the Ser380 residue in Xenopus RSK1 that has been found to be an autophosphorylation site [12] and is phosphorylated upon mitogen stimulation in rat RSK1 [10] . D2 encodes the carboxy-terminal kinase domain (Figure 1 ).
When expressed in HEK 293E cells and stimulated with serum, D1′ was active towards the substrate, a fusion protein between glutathione-S-transferase and a ribosomal S6 protein peptide (GST-S6), whereas D1 was not ( Figure 2 ). Even in the absence of serum, D1′ exhibited a significant level of basal activity. The K112R mutation abolished D1′ phosphotransferase activity. Mobility shifting of endogenous RSK indicated that the cells were serum-stimulated; therefore the lack of phosphotransferase activity in D1 was not due to lack of stimulation. These data suggest that the additional amino acids are critical for the activation of the RSK1 amino-terminal kinase domain.
The isolated D2 kinase domain was also expressed in cells (Figure 3a,b) . In serum-stimulated cells, D2 was active towards exogenous GST-D2 (K464R) and, interestingly, D2 also underwent a significant amount of autophosphorylation (Figure 3c,d ). Again, a K464R mutation reduced kinase activity of this domain.
Because of the known contribution of ERK to RSK activation, we examined the effect of blocking ERK activation on the kinase activity of each isolated kinase domain ( Figure 4 ). Cells transfected with either HA-D1′ or HA-D2 Research Paper RSK1 activation by ERK and PDK1 Richards et al. 811
Figure 1
Constructs encoding full-length (FL) RSK, D1, D1′ and D2 were generated. Each construct was fused at the 5′ end to sequences encoding a triple hemagglutinin (HA) epitope tag. White boxes, kinase domains; numbers, amino-acid positions; identified phosphorylation sites are S239, T377, S381, S398, T590 and S749; diamonds, inactivating mutations in each kinase domain. Amino-acid residues are indicated in the single-letter amino-acid code. The RSK clone used was avian RSK1, which encodes an avian-specific epitope between amino-acid residues 37 and 54 (Av epitope). were treated with the MEK inhibitor PD098059 before serum stimulation, and phosphotransferase activity was measured. For HA-D1′, PD098059 treatment severely curtailed serum-stimulated kinase activity towards GST-S6, but had no effect on the electrophoretic mobility of HA-D1′ (Figure 4a ). For HA-D2, PD098059 treatment also reduced its phosphotransferase activity, both towards an exogenous substrate and its autophosphorylation (Figure 4b ). Interestingly, HA-D2 still underwent a serum-stimulated mobility shift, suggesting that HA-D2 may be phosphorylated by a mitogen-dependent MEK-independent kinase.
RSK1 is phosphorylated by PDK1 and ERK in vitro
We have thus far demonstrated that isolated RSK1 kinase domains can be activated in vivo. The signals responsible for that activation have not been completely elucidated, however. It is well established that ERK phosphorylation is a critical event for RSK1 activation. ERK binds the RSK1 carboxyl terminus [2, 25, 26] and phosphorylates a site within the activation loop of the carboxy-terminal kinase domain [11] . Activated ERK also activates the RSK1 carboxy-terminal autophosphorylation activity in vitro [2] . Mutation of the putative ERK phosphorylation site in fulllength RSK1 reduces RSK1 amino-terminal kinase activity towards exogenous substrate ( [10] ; data not shown), reinforcing the importance of this phosphorylation event. In avian RSK1, this phosphorylation site is Thr590. When GST-D2 (K464R) was used as a substrate for activated ERK1 in an in vitro kinase reaction, it was found to be phosphorylated (Figure 5a ), but the phosphorylation was eliminated when the substrate contained a T590A mutation. We conclude that Thr590 in avian RSK1 is an ERK phosphorylation site.
Signals required for the activation of the amino-terminal kinase domain are less well understood, and are of particular interest as all exogenous RSK substrates are phosphorylated by this kinase domain. Four phosphorylation sites have been identified within this region in rat RSK1 [10] . In avian RSK1, these sites are Ser239, Thr377, Ser381 and Ser398 (in rat RSK1, the corresponding sites are Ser222, Thr360, Ser364 and Ser381). Sequence comparison suggested that the Ser239 residue of avian RSK1 was either an autophosphorylation site or a site phosphorylated by PDK1 ( [10] ; Figure 5b ). To test the hypothesis that PDK1 phosphorylates the RSK1 amino terminus, a GST-D1′ fusion protein was made; a second GST-D1′ fusion protein carrying a point mutation (S239A) at the putative PDK1 site was also generated. When purified GST-D1′ (K112R) and GST-D1′ (K112R, S239A) were used as substrates in an in vitro kinase assay, only GST-D1′ (K112R) was phosphorylated by PDK1 (Figure 5c , upper panel); the S239A mutant was not phosphorylated. The lack of phosphorylation in the S239A mutant also indicated that the GST moiety was not phosphorylated by PDK1. PDK1 was active in both kinase reactions, as indicated by its autophosphorylation T590  T590  T590A  T590A GST-ERK1* GST-ERK1 (K52R)
Substrate GST-D2 (K464R):
and GST-PKCζ as substrates (see Supplementary material). With equimolar amounts of substrate under linear reaction conditions, Myc-PDK1 phosphorylated both GST-D1 and GST-PKCζ, with PKCζ phosphorylation slightly higher (1.5-2-fold) than GST-D1 RSK.
Finally, we examined the ability of PDK1 to phosphorylate full-length RSK in vitro. A kinase-deficient RSK was immunoprecipitated from quiescent cells and incubated with GST-PDK1. As shown in Figure 5d , the full-length protein was phosphorylated by PDK1 (lane 2) but not by a kinase-deficient PDK1 (lane 3). Because this RSK fusion protein was catalytically inactive, the RSK phosphorylation is not due to autophosphorylation activity.
The data presented above suggest that RSK is phosphorylated by PDK1, and that S239 in RSK1 is a PDK1 phosphorylation site. This is the first indication that a regulatory input other than from ERK plays a role in RSK1 activation.
PDK1 activates an isolated RSK1 amino-terminal kinase domain
Because PDK1 phosphorylates the RSK1 amino terminus in vitro, we tested the effect of PDK1 on D1′ activation in vivo. HEK 293E cells were cotransfected with D1′ and increasing amounts of either wild-type PDK1 or the kinaseinactive PDK1 (K110N). Figure 6a shows that increasing amounts of PDK1 increased D1′ kinase activity towards the exogenous substrate. Surprisingly, D1′ activation by PDK1 alone approached the activation level induced by serum. Coexpression of the kinase-inactive PDK1 (K110N) mutant actually decreased basal D1′ kinase activity, a result consistent with the finding that the S239 site is basally phosphorylated [10] . PDK1 (K110N) may reduce basal phosphorylation at S239, thereby decreasing basal phosphotransferase activity. These results suggest that PDK1 alone can activate the RSK1 amino-terminal kinase domain.
Although the in vitro phosphorylation of D1′ by PDK1 suggests that the phosphorylation is direct, it is possible that the overexpression of PDK1 could induce activation of various PKCs, which could indirectly activate D1′ through the ERK/MAP kinase pathway. To address this possibility, we expressed an S239A D1′ mutant in the presence of PDK1 and a constitutively active MEK-1 protein in which serine residues 218 and 222 were substituted by aspartic acid residues (MEK-DD) and examined mobility shifts; because a S239A mutation renders the amino-terminal kinase domain inactive ( [10] ; data not shown), kinase assays to examine the effect on activity are not possible. Figure 6b shows that when S239 is mutated to alanine in D1′, the doublet seen in the wildtype protein is replaced by a single band of faster mobility. No mobility shift was seen in D1′ (S239A) upon serum stimulation or cotransfection with PDK1 or MEK-DD. For wild-type D1′, intensification of the upper band was seen upon coexpression with PDK1 but not with MEK-DD. While this result does not eliminate the possible indirect contribution of other kinases activated by PDK1, it does suggest that the slower-migrating form of D1′ is the result of basal phosphorylation, and that this phosphorylation is not a direct result of activation of the ERK/MAP kinase pathway. 
PDK1 is not sufficient to activate full-length RSK1
We have established that PDK1 alone can activate phosphotransferase activity of the isolated amino-terminal kinase domain of RSK1, and we next investigated the effect of PDK1 on full-length RSK1, which carries both kinase domains. HEK 293E cells were cotransfected with fulllength RSK1 and PDK1 (Figure 7a ), and RSK1 activity was assayed. At higher expression levels, PDK1 induced a small activation of RSK1 kinase activity, but did not approach the level induced by serum. Under these conditions, immunoprecipitated Myc-PDK1 coprecipitated HA-RSK1, as detected by western blotting, indicating that the two proteins are interacting (Figure 7c ). RSK activation was slightly enhanced upon coexpression of PDK1 with RSK in serumstimulated cells, although fold-activation was slightly lower, possibly as a result of higher basal activity (Figure 7b ).
Although PDK1 could phosphorylate full-length RSK1 in vitro (Figure 5d) , it was possible that PDK1 did not regulate the phosphorylation of full-length RSK1 in vivo. To examine this possibility we took advantage of the observation that phosphorylation of wild-type full-length RSK affects its mobility in SDS-polyacrylamide gels [27] . In quiescent cells, RSK1 existed primarily as a faster-migrating species but, upon activation by serum, slower-migrating middle and upper bands were observed (Figure 8a ). Coexpression with PDK1 in the absence of serum induced a shift in wild-type RSK1 to the middle band, implying that full-length RSK1 can be phosphorylated upon coexpression with PDK1. A shift to the uppermost band was never observed, however.
To confirm that PDK1 induced a mobility shift in fulllength RSK1 in vivo, an S239A mutation was introduced into full-length RSK1. This mutation renders the phosphotransferase activity of the RSK1 amino-terminal kinase domain inactive ( [10] ; data not shown). When RSK1 (S239A) was expressed in cells, serum stimulation was still able to induce a shift to the slower-migrating band ( Figure 8a) ; in the absence of serum, however, PDK1 did not induce a shift to a slower-migrating species. This is in contrast to the shift induced in wild-type RSK1 under these conditions. These data suggest that, although PDK1 does not activate full-length wild-type RSK1, it is capable of inducing RSK1 phosphorylation in vivo.
The serum-induced shift in RSK1 (S239A) could be the result of phosphorylation of the carboxyl terminus and autophosphorylation by this activated carboxy-terminal kinase domain. The amino-terminal kinase domain is inactive [10] , but to test whether the carboxy-terminal kinase domain of this mutant was active, kinase assays were performed with immunoprecipitated RSK1 (S239A), using GST-D2 (K464R) as substrate. As seen again in Figure 8b , RSK1 (S239A) underwent a shift upon serum stimulation (lower panel). This shift correlated with both the ability of the carboxyl terminus to phosphorylate the exogenous substrate (upper panel) and the ability to autophosphorylate (data not shown). To examine whether the activation of the carboxy-terminal kinase domain was solely due to ERK phosphorylation, RSK1 (S239A) was coexpressed with increasing amounts of MEK-DD. While coexpression with MEK-DD induced a mobility shift in the S239A mutant of RSK1 (lower panel), it was not sufficient to activate carboxy-terminal-domain kinase activity towards GST-D2 (K464R) -the exogenous substrate (upper panel) -or for autophosphorylation (data not shown). These results suggest that, for RSK1 (S239A), inactivation of the aminoterminal kinase domain does not affect the ability of the carboxy-terminal kinase domain to be activated by mitogenic stimuli such as serum, nor does it block presumed autophosphorylation. Nevertheless, full activation of the RSK1 carboxyl terminus requires inputs in addition to ERK, either by autophosphorylation by the amino-terminal kinase domain or by other mitogen-activated kinases.
MEK-DD and PDK1 cooperate to activate full-length RSK1
RSK1 activation requires interaction between the RSK1 carboxyl terminus and ERK [25] , and blocking MEK activation with PD098059 decreases RSK1 activation [28] . We therefore examined the possibility that both ERK and PDK1 are required for RSK1 activation. To do this, RSK1 activity was first assayed upon coexpression with increasing amounts of MEK-DD in HEK 293E cells; MEK-DD causes constitutive activation of ERK [29] . As seen in Figure 9 , higher doses of MEK-DD could significantly activate RSK1 phosphotransferase activity. To investigate whether there was a co-operative effect with PDK1, subactivating levels of MEK-DD were chosen: 0.25 and 0.5 µg. We then expressed full-length RSK1 with both MEK-DD and PDK1. As seen above and in Figure 10 , expression of wild-type RSK1 with either MEK-DD (lanes 3,6) or PDK1 alone (lanes 9,10) did not significantly activate RSK1 kinase activity. When MEK-DD and PDK1 were coexpressed, however, RSK1 phosphorylation of GST-S6 was activated at a level higher than with either PDK1 or MEK-DD alone (lanes 4,5 and 7,8) , and this activation was dose dependent. Therefore, MEK-DD and PDK1 cooperatively activate RSK1.
Discussion
Activation of RSK1 has been thought to be dependent solely on phosphorylation by activated ERK and subsequent RSK1 autophosphorylation. We have shown here that PDK1 phosphorylates wild-type avian RSK1 and is even capable of activating the isolated RSK1 amino-terminal kinase domain. Furthermore, cooperation between ERK and PDK1 can produce an active RSK1 enzyme. The contribution of PDK1 means that we have uncovered an additional signaling pathway involved in the regulation of RSK1.
That phosphorylation by ERK is critical for RSK1 activation is indisputable. The observation that mutation of the ERK phosphorylation site in the RSK1 carboxyl terminus severely compromises mitogen-stimulated RSK1 kinase activity ( [10] ; data not shown) reinforces this supposition.
Preventing ERK activation by inhibiting upstream MEK with PD098059 blocks RSK1 activation [28] . There have been indications, however, that ERK is not sufficient for full activation of RSK1; activation of quiescent RSK in vitro with activated ERK restores only a portion of RSK1 phosphotransferase activity [30] . Although we have shown here that an isolated amino-terminal RSK1 kinase domain is readily activated by PDK1, this contribution would be masked in the full-length protein because of the requirement for ERK in RSK1 activation. The role of PDK1 would be concealed under conditions where ERK is quiescent. We propose a model for RSK1 activation that incorporates the requirements for phosphorylation by ERK and PDK1, as well as other activating phosphorylation events (Figure 11 ).
The PDK1 phosphorylation site identified here in RSK1 is preserved in all three human RSK isoforms: RSK1, RSK2, and RSK3 [31] . In a patient diagnosed with Coffin-Lowry syndrome, the PDK1 phosphorylation site is mutated in RSK2, and several patients lack active RSK2 [32] . Coffin-Lowry syndrome is characterized by mental retardation, various musculoskeletal defects and motor difficulties. This suggests that RSK enzyme activity could be involved in normal development.
The RSK carboxy-terminal kinase domain is homologous to the mitogen-and stress-activated protein kinases MNK1 and MNK2, which are also phosphorylated by ERK [33, 34] . We have previously shown that the RSK carboxy-terminal kinase domain is active in vitro [2] . Here, we have extended the characterization to demonstrate that the catalytic activity exhibited by this kinase domain is regulated in vivo in response to growth stimuli.
The RSK amino-terminal kinase domain is homologous to the kinase domains in other members of the AGC family, which includes PKA, various PKCs, and p70 S6K1 (Figure 5b ; reviewed in [35] ). The PDK1 phosphorylation site in RSK1 is similar to PDK1 sites in these other enzymes, suggesting that this a general regulatory site for these kinases. Using immunoprecipitated PDK1, similar levels of in vitro phosphorylation were seen with equimolar amounts of GST-D1 (K112R) and GST-PKCζ, a known PDK1 substrate (data not shown). This site was found to be basally phosphorylated in RSK1, with a further increase in phosphorylation upon stimulation with phorbol myristoyl acetate [10] . This basal phosphorylation is consistent with our observations that D1′ has high basal activity relative to the serum-stimulated activity level, and that expression of a kinase-inactive PDK1 can decrease D1′ basal phosphotransferase activity.
Although PDK1 does phosphorylate Akt/PKBα, p70 S6K1 and RSK1, there are differences in the phospholipid requirement for this phosphorylation. For Akt/PKBα, this reaction is dependent on phospholipids [15, 16, 36, 37] . Binding of phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P 2 ) or PtdIns(3,4,5)P 3 to the PH domain of Akt/PKBα, targets the enzyme to the membrane and brings it into proximity with membrane-associated PDK1.
Phosphorylation of p70 S6K1 by PDK1 is independent of phospholipids [21, 22] , and the ability of PDK1 to phosphorylate RSK1 in vitro suggests that this reaction is also phospholipid independent.
There are also differences in how PDK1 collaborates with different inputs to fully activate a kinase. With Akt/PKBα, it has been suggested that accessibility of the PDK1 phosphorylation site is regulated by binding of PtdIns(3,4)P 2 /PtdIns(3,4,5)P 3 to the Akt/PKBα PH domain [23] . This induces a conformational change, rendering the PDK1 site on Akt/PKBα accessible. With p70 S6K1 , PDK1 cooperates with Rho family GTPases, PI 3-kinase, and inputs regulated by mTOR or FK506-binding protein (FKBP)-rapamycin associated protein (FRAP) ( [38] ; data not shown). PDK1 phosphorylation and activation of p70 S6K1 requires prior phosphorylation of residues in the p70 S6K1 regulatory domain [22] . In this case, phosphorylation is used instead of phospholipid binding to achieve the same goal: a conformational change exposing a PDK1 phosphorylation site.
Here, we have shown that RSK1 activation requires cooperation between the Ras-ERK/MAP kinase pathway and PDK1. RSK1 is unique in that activation of one kinase domain requires activation of another. Nature has solved the problem of bringing these two kinases together by fusing the RSK carboxy-terminal kinase domain (homologous to MNK1/MNK2) to the amino-terminal kinase domain (homologous to the AGC superfamily of kinases). Activation of RSK1 phosphotransferase activity towards exogenous substrates necessitates the convergence of the two signaling pathways, with each kinase domain requiring a different signal: the carboxy-terminal kinase domain requires phosphorylation by ERK, and the amino-terminal kinase domain requires phosphorylation by PDK1.
Full-length RSK1 and PDK1 can be coimmunoprecipitated from quiescent cells, suggesting that they interact in vivo. The phosphorylation of quiescent full-length RSK1 by PDK1 without activating the amino-terminal kinase domain suggests that the PDK1 site in RSK1 is accessible. This phosphorylation is quite different from PDK1 phosphorylation of Akt/PKBα and p70 S6K1 . In this regard, RSK1 may be similar to PKA, whose basal phosphorylation at the PDK1 site is co-translational [20, 39, 40] . If this were also the case for RSK1, it may explain the inability of a dominant-negative PDK1 to antagonize serum-stimulated RSK1 activation (data not shown). We also suggest that, when quiescent, the RSK1 carboxyl terminus acts as a negative regulator of the amino-terminal kinase domain. We have shown here that phosphotransferase activity of the isolated RSK1 aminoterminal kinase domain can be activated by PDK1 alone, but the full-length RSK1 cannot; activation of full-length RSK1 requires activated ERK.
818 Current Biology, Vol 9 No 15
Figure 11
Model of RSK1 activation by PDK1 and ERK. We propose that PDK1 phosphorylates RSK1, even when RSK1 is quiescent. The RSK1 carboxyl terminus acts as a negative regulator, blocking activation of the amino-terminal kinase domain. Upon mitogen stimulation, ERK becomes activated and phosphorylates the RSK1 carboxyl terminus. This phosphorylation activates the RSK1 carboxy-terminal kinase domain and stimulates RSK1 autophosphorylation by this domain. Activation of the carboxy-terminal kinase domain induces a conformational change, abrogating the negative regulatory effect of this domain. The RSK1 amino-terminal kinase domain is then freed to phosphorylate exogenous substrates. P, phosphate groups. [10] . In addition, S398, which has been identified as a RSK autophosphorylation site [12] is a consensus sequence for PDK2 phosphorylation [41] .
Further studies addressing the autoregulation of the individual kinase domains and the interactions between RSK1 and regulatory kinases will be important for understanding the regulatory role of other RSK1 phosphorylation sites. The data presented here support a role for an ERK-independent event in regulating RSK1 kinase activity. This finding introduces both new clarity and increased complexity in understanding the role of RSK1 in cell proliferation and survival signaling.
Conclusions
PDK1 and ERK act cooperatively to activate phosphotransferase activity of the serine/threonine kinase RSK1. Our results show that, in addition to having an important role in signaling to kinases regulated by PI 3-kinase, PDK1 also participates in Ras-ERK/MAP kinase signaling through RSK1.
Materials and methods
Plasmid constructs
Avian RSK1 was subcloned into pKH3, which encodes a triple HA tag at the amino terminus [42] . Avian RSK1 contains an avian-specific epitope between amino acids 37 and 54. The S239A mutant was generated using Stratagene's QuikChange kit. D1, D1′ and D2 in pKH3 were generated by PCR. D1′ (K112R) in pGEX-2T was generated by PCR using avian RSK1 (K112R) as target, and this was then used as target DNA for PCR-based site-directed mutagenesis to generate the D1′ (K112R, S239A) in pGEX-2T. A similar strategy was used to generate GST-D2 (K464R) with and without the T590A mutation. MEK-DD in pCDNA3 was a gift from R. Erikson. Wild-type and K110N versions of Myc-PDK1 in pCDNA3 were previously described [17] .
Cell culture, transfection and lysis
HEK 293E cells were grown in DME with 10% FBS in 6% CO 2 . Cells were transfected with CaPO 4 for 5 h with 1 µg RSK with a total of 5 µg DNA per 60 mm dish unless otherwise indicated; DNA quantities were equalized with empty vector pRK7. Cells were rinsed with PBS and starved in DME without serum for 16 h. Where indicated, cells were stimulated with 10% calf serum at 37°C, 6% CO 2 for 10 min. Cells were rinsed with PBS on ice before lysis in cell-lysis buffer (10 mM KPO 4 , 1 mM EDTA, 5 mM EGTA, 10 mM MgCl 2 , 50 mM β-glycerophosphate, 0.5% NP-40, 0.1% Brij-35, 0.1% deoxycholic acid, 1 mM sodium orthovanadate, 2 mM DTT, 1 mM PMSF, 5 µg/ml pepstatin and 10 µg/ml leupeptin). Lysates were centrifuged at 14,000 rpm at 4°C for 10 min before separating into aliquots and storage at -80°C.
Western blotting
Lysates were subjected to SDS-PAGE and transferred to nitrocellulose. The filter was blocked with 3% milk/TBS-Tween for 1 h at room temperature. Primary antibody treatment was for 1 h at room temperature. Polyclonal antibody against the RSK1 avian-specific epitope (1:5,000), and polyclonal anti-RSK1 (1:500) and anti-MAP kinase (1:2,000) antibodies were generated as described [2] . Anti-HA (1:60,000) and anti-Myc (1:2,000) antibodies were used where indicated. Blots were washed with TBS-T before treatment with either goat anti-mouse HRP (1:30000 for quantitative ECL) and anti-rabbit HRP (1:5,000) for 1 h at room temperature. Blots were visualized by ECL (NEN) or quantitated by ECL on a BioRad FluorS with BLAZE ECL reagents (Pierce).
Immunoprecipitation kinase assays
For RSK1 kinase assays, antibody to the HA epitope tag was added to cell lysates and incubated at 4°C for 2 h. Immunoprecipitation kinase assays with GST-S6 were performed as described [43] . Because the RSK1 carboxy-terminal kinase domain does not phosphorylate GST-S6, GST-D2 (K464R) was used as a substrate to assay carboxy-terminal kinase activity of RSK1. For MAP kinase kinase assays, anti-MAP kinase antibody was added to lysates and the assay was performed as for anti-RSK1 antibody assays except using GST-D2 (K464R) as substrate [2] . Reactions were subjected to SDS-PAGE and quantitated on a BioRad Phosphorimager.
In vitro kinase assays
Substrate GST fusion proteins were purified with glutathione-sepharose beads (Pharmacia). For in vitro ERK phosphorylation, GST-ERK* and GST-ERK K52R* were activated with MEK1 and purified [2] . For in vitro PDK1 phosphorylation, Myc-PDK1 was immunoprecipitated from transiently transfected HEK 293E cells and washed once each with buffer A (10 mM Tris pH 7.2, 1% NP-40, 0.5% sodium deoxycholate, 100 mM NaCl, 1 mM EDTA, 0.5% sodium orthovanadate, 2 mM DTT, 100 mM PMSF), buffer B (same as buffer A except 0.1% NP-40 and 1 M NaCl), and ST (50 mM Tris-HCl, 5 mM Tris-Base, 150 mM NaCl) before resuspension in kinase buffer [43] . All reactions were carried out with 10 µCi [γ-32 P]ATP (NEN) per reaction at 30°C for 15 min. Before stopping the Myc-PDK1 reactions, samples were placed on ice and centrifuged 10 min at 14,000 × g at 4°C to precipitate Myc-PDK1. Supernatant and pellet fractions were run separately. Reactions were resolved by SDS-PAGE and exposed to film.
Supplementary material
Supplementary material, including in vitro kinase assays performed using GST-D1 RSK and GST-PKCζ as substrates, is available at http://current-biology.com/supmat/supmatin.htm.
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Figure S1
In vitro phosphorylation of GST-D1 K112R with GST-PKCζ (Z) by Myc-PDK1. HEK 293E cells were transfected for 5 h with 1 µg Myc-PDK1, rinsed and recovered in DMEM containing 10% foetal bovine serum. After 16 h, cells were lysed and treated with an anti-Myc antibody to precipitate Myc-PDK1. The indicated amounts of GST-substrate were added to PDK1 immunoprecipitates in an in vitro kinase reaction that contained [γ-32 P]ATP. After 20 min at 30°C, reactions were placed on ice and spun at 14,000 x g for 10 min at 4°C. Sample buffer was added to the supernatant, which was then separated by SDS-PAGE. Phosphate incorporation was quantitated on a phosphorimager. The data show that MycPDK1 phosphorylates GST-D1 K112R and GST-PKCζ at comparable levels in vitro. 
